Kamada (KMDA)
(Delayed Data from NSDQ)
$5.78 USD
-0.05 (-0.86%)
Updated Jul 19, 2024 04:00 PM ET
After-Market: $5.88 +0.10 (1.73%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
KMDA 5.78 -0.05(-0.86%)
Will KMDA be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for KMDA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for KMDA
Zymeworks (ZYME) Stock Up 29% in Three Months: Here's Why
Mesa Labs and Eldorado Gold have been highlighted as Zacks Bull and Bear of the Day
KMDA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Sanofi's (SNY) Dupixent & Vaccines Make the Stock Attractive
3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying
Merck (MRK) Inks Deal to Develop Antibodies for Treating Cancer
Other News for KMDA
Buy Rating Affirmed for Kamada on Accelerated Trial Prospects and Strong Financial Performance
KMDA Stock Earnings: Kamada Misses EPS, Misses Revenue for Q1 2024
Kamada Ltd. (KMDA) Q1 2024 Earnings Call Transcript
Kamada Ltd. Reports Strong Growth and Raises Guidance
Kamada GAAP EPS of $0.04 misses by $0.02, revenue of $37.7M misses by $0.24M